DaVita HealthCare Partners Inc (DVA): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

DaVita HealthCare Partners ( DVA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 2.0%. By the end of trading, DaVita HealthCare Partners fell $0.90 (-1.4%) to $64.74 on average volume. Throughout the day, 1,836,088 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 2,080,900 shares. The stock ranged in price between $64.39-$65.85 after having opened the day at $65.85 as compared to the previous trading day's close of $65.64. Other companies within the Health Care sector that declined today were: Chelsea Therapeutics International ( CHTP), down 29.2%, Mast Therapeutics ( MSTX), down 27.7%, MannKind Corporation ( MNKD), down 16.4% and Aegerion Pharmaceuticals ( AEGR), down 10.8%.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $13.9 billion and is part of the health services industry. The company has a P/E ratio of 24.6, above the S&P 500 P/E ratio of 17.7. Shares are up 3.6% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Rexahn Pharmaceuticals ( RNN), up 70.0%, Intercept Pharmaceuticals ( ICPT), up 61.6%, Conatus Pharmaceuticals ( CNAT), up 45.4% and Endocyte ( ECYT), up 28.6% , were all gainers within the health care sector with Perrigo Company ( PRGO) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Stocks Lose Steam as Yields Hover Near 3% Threshold

Stocks Lose Steam as Yields Hover Near 3% Threshold

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists